← Eichor
Condition: Breast Cancer Risk Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Breast Cancer Risk

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Phase 4 · 34 location(s) · Fudan University · NCT04790305Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
Phase 3 · 9 location(s) · Uppsala University · NCT04722692MELIORA Virtual Coach Intervention for Breast Cancer Prevention
NA · 7 location(s) · Harokopio University · NCT07200427NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
Phase 2 · 1 location(s) · Medical University of South Carolina · NCT06845319Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06635980Rutgers University Study of the Genetics of Breast Cancer.
Phase N/A · 1 location(s) · Rutgers, The State University of New Jersey · NCT06773897Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Eva
Phase 2 · 4 location(s) · M.D. Anderson Cancer Center · NCT07076485A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ov
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT07532434Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined
Phase N/A · 1 location(s) · Shu Wang · NCT06711068Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
Phase 1 · 1 location(s) · Duke University · NCT07264790Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NA · 11 location(s) · University of California, San Francisco · NCT02620852Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Phase 2 · 3 location(s) · National Cancer Institute (NCI) · NCT06195306HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).
NA · 1 location(s) · Post Graduate Institute of Medical Education and Research, C · NCT04472845Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Phase N/A · 1 location(s) · Institut fuer Frauengesundheit · NCT07531693CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients
Phase 3 · 1 location(s) · Fudan University · NCT07019363Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer
NA · 1 location(s) · Ruijin Hospital · NCT05976412Endoscopy/Robotic Assisted Nipple Skin Sparing Mastectomy
Phase N/A · 1 location(s) · Alejandra García-Novoa · NCT06823414A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · 284 location(s) · Novartis Pharmaceuticals · NCT06830720Alternative Physical Activity Strategies for Breast Cancer Survivors
NA · 1 location(s) · University of Toronto · NCT06633380Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06559696MELIORA Data Collection Campaigns
NA · 7 location(s) · Harokopio University · NCT07190066A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · 709 location(s) · AstraZeneca · NCT05774951Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
Phase 2 · 1 location(s) · Andrea DeCensi · NCT06364267Super-Hypofractionated Partial Breast Irradiation
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06615466TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women Wit
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05667532Night-shift Work and Breast Cancer
Phase N/A · 2 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06786949Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07179744
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.